Vasculitis
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Dr. John Cush RheumNow
1 year ago
RCT of #upadacitinib in #GCA
It works to steroid spare
15 mg > 7.5 mg in outcomes
Both >>placebo
Ethically PBO had slower #prednisone taper
Similar to #TCZ data
What to choose in GCA
IL6i?
IL17i?
JAKi?
@eular_org
# LBA0001 @Janetbirdope https://t.co/DGOltriVYF

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action.
There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Janet Pope Janetbirdope
1 year ago
Summary of #EULAR2024 #ClinicalPearls
JAKi have expanding disease data
✅ #GCA w #UPA
✅ Awaiting data in #SLE w #UPA & #Deucravacitinib
✅Use in #JIA
✅No new safety signals
@rheumnow
@eular_org

Janet Pope Janetbirdope
1 year ago
Once in remission with
#rituximab in #GPA
How long to resize
500 mg q6 mo for
4 years?
?longer
?less
#EULAR2024 @eular_org @RheumNow https://t.co/G4kU3v81je

Janet Pope Janetbirdope
1 year ago
#EULARBEST
RCT of #upadacitinib in #GCA
It works to steroid spare
15 mg > 7.5 mg in outcomes
Both >>placebo
Ethically PBO had slower #prednisone taper
Similar to #TCZ data
What to choose in GCA
IL6i
IL17i
JAKi
@eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo

David Liew drdavidliew
1 year ago
PMR patients get too much steroid.
Data across 27 million people in England, n=39,438 with PMR.
The blue are getting more pred than guidelines.
Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help.
#EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm


Md Yuzaiful Md Yusof Yuz6Yusof
1 year ago
#EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S


Peter Nash drpnash
1 year ago
EULAR Abstract Archive
OP0283 (2024)
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Md Yuzaiful Md Yusof Yuz6Yusof
1 year ago
#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2


Mrinalini Dey DrMiniDey
1 year ago
LBA0001 UPA in GCA- Phase 2 RCT
15mg UPA with 26w steroid taper showed
⬆️ efficacy
⬇️ steroid use
vs placebo with 52w steroid taper
Potential new target on the horizon for #GCA??
@RheumNow #EULAR2024

Rheumatology & Rheumatology Advances in Practice RheumJnl
1 year ago
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀
➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
